Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma

First-in-Human (FIH), Open-Label, Non-Randomized, Single-Arm Phase 1 Study to Evaluate the Safety and Tolerability of Donor-Derived CD5 CAR T (CT125B) Cells ForRelapsed or Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma

This is a FIH, single center, open label, non-randomized, single-arm, Phase I clinical trial to evaluate the safety and tolerability of CD5 CAR T (CT125B) cells in subjects with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma. 9-18 subjects will be enrolled. After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m^2/day and cyclophosphamide at 250 mg/m^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.

Then this study will be using BOIN1/2 approach from starting dose 1: 1×10^6 (±20%) to dose 2: 2×10^6 (±20%). If the manufactured cells were not sufficient to meet the preassigned standard dose criteria, patients are given infusion at a low dose of 5×10^5 (±20%) /kg.

Study Overview

• Status: Withdrawn
• Conditions: T-Cell Acute Lymphoblastic Leukemia/Lymphoma
• Intervention / Treatment: Biological: CD5 CAR T (CT125B)

• Study Type: Interventional
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100070
      • Beijing Gaobo Boren Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year to 70 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Candidates with relapsed or refractory CD5+ T cell acute lymphoblastic leukemia/lymphoma, who have progressed after treatment with all standard therapies or been intolerant of standard care, have limited prognosis with currently available therapies and had no available curative treatment options (such as SCT or chemotherapy)
2. Male or female, aged 1-70 years
3. No serious allergic constitution
4. Eastern Cooperative Oncology Group (ECOG) performance status (Oken et al., 1982) score 0 to 2
5. Have life expectancy of at least 60 days based on investigator's judgement
6. CD5 positive on blasts in bone marrow or CSF by flow cytometry, or CD5 positive on tumor tissues by immunohistochemistry; (CD5 positive criteria: Flow cytometry: Positive: > 80% of tumor cells expressed CD5 and the mean fluorescence intensity (MFI) of CD5 is the same as that in normal T cells; Dim: > 80% of tumor cells expressed CD5, but the MFI of CD5 is lower than that in normal T cells as least as 1 log; Partial positive: 20-80% of tumor cells expressed CD5 and the MFI of CD5 is the same as that in normal T cells. Tumor tissue immunohistochemistry: Positive > 30% tumor cells expressed CD5)
7. Provide a signed informed consent before any screening procedure. Patients who voluntarily participate in the study should have the ability to understand and sign the informed consent form (ICF) and be willing to follow the visit schedule and relevant study procedure, as specified in the protocol. Candidates aged 19-70 years old need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form. Candidates of 8-18 years old need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form, besides, their legal guardian or patient advocate also need to sign the treatment consent form and voluntary consent form. Children candidates of 1-7 years old can be recruited after the legal guardian or patient advocate need to sign the treatment consent form and voluntary consent form.
8. Have suitable and available allogeneic hematopoietic stem cell transplantation donor, and is willing to proceed to SCT if achieve CR.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Intracranial hypertension or disorder of consciousness
2. Symptomatic heart failure or severe arrhythmia
3. Symptoms of severe respiratory failure
4. Complicated with other types of malignant tumors
5. Diffuse intravascular coagulation
6. Serum creatinine and / or blood urea nitrogen ≥ 1.5 times of the normal value
7. Suffering from septicemia or other uncontrollable infections
8. Patients with uncontrollable diabetes
9. Severe mental disorders
10. Obvious and active intracranial lesions were detected by cranial magnetic resonance imaging (MRI)
11. Have received organ transplantation (excluding bone marrow transplant)
12. Reproductive-aged female patients with positive blood HCG test
13. Screened to be positive of infection of hepatitis (including hepatitis B and C), AIDS or syphilis
14. Post-CAR SCT is not feasible in patients
15. No donor is applicable for peripheral blood mononuclear cell (PBMC) collection or no frozen donor's PBMC is available for manufacturing CAR T cells.
16. Patients unable to discontinue nucleoside antiviral drugs that have a similar mechanism to ganciclovir

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: CD5 CAR T (CT125B); All patients who receive CD5 CAR T (CT125B) cell infusion.

Biological: CD5 CAR T (CT125B); Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m^2/day and cyclophosphamide at 250 mg/m^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence and type of dose-limiting toxicity (DLT)	DLT assessment according to the clinical study protocol.	21 days post intravenous injection
Incidence and severity of adverse events (AE)	Incidence and severity of adverse events as assessed by NCI-CTCAE 5.0.	30 days post intravenous injection

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective response rate (ORR)	Objective response rate (ORR) according to NCCN.	30 days post infusion
Counts and persistence of CAR T cells	Blood samples for determination of persistence/counts of infused CAR T cells will be analysed.	30 days post infusion
Incidence and grade of severe adverse events (SAEs)	Incidence and severity of severe adverse events as assessed by NCI-CTCAE 5.0.	2 years post infusion
Best overall response (BOR) rate	Best overall response (BOR) rate according to NCCN.	3 months post infusion
The counts of CART cells after using CAR T suicidal switch drugs .	The counts of CART cells change when CAR T suicidal switch drugs ( ganciclovir ) are used for 3 days and 7 days respectively.	7 days post administration of ganciclovir

Collaborators and Investigators

• Sponsor: Beijing Boren Hospital
• Investigators: Principal Investigator: Jing Pan, MD/PhD, Beijing Gaobo Boren Hospital

Study record dates

Study Major Dates

• Study Start (Actual): August 3, 2022
• Primary Completion (Actual): December 31, 2023
• Study Completion (Actual): December 31, 2023

Study Registration Dates

• First Submitted: August 1, 2022
• First Submitted That Met QC Criteria: August 3, 2022
• First Posted (Actual): August 4, 2022

Study Record Updates

• Last Update Posted (Estimated): November 14, 2024
• Last Update Submitted That Met QC Criteria: November 12, 2024
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Keywords: CAR-T; Leukemia; acute lymphoblastic leukemia/lymphoma
• Additional Relevant MeSH Terms: Neoplasms; Immune System Diseases; Neoplasms by Histologic Type; Hematologic Diseases; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Leukemia; Lymphoma; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
• Other Study ID Numbers: BRYY-IIT-LCYJ-2022-026

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No